TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06454747
Drug: SM-030 gel 0.08%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application to face twice daily for 12 weeks.
Study: NCT06790927
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.
Study: NCT06764940
Drug: Utidelone in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study: NCT06764940
Drug: Utidelone in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study: NCT06764940
Drug: Utidelone in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study: NCT06752122
Drug: Placebo (in SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation once daily in the SAD part
Study: NCT06752122
Drug: RCS-21 (in SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation once daily in the SAD part
Study: NCT06752122
Drug: Placebo (MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation once daily for seven days in the MAD part
Study: NCT06752122
Drug: RCS-21 (in MAD)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation once daily for seven days in the MAD part
Study: NCT06798571
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/day patch
Study: NCT06762548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo solution
Study: NCT06596356
Drug: [14C] TS-172
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
Study: NCT04962139
Drug: ON101 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Study: NCT04968184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will orally receive placebo matching to KBP-5074 tablets QD.
Study: NCT05322616
Drug: JK07
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
Study: NCT05322616
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control
Study: NCT06772766
Drug: 9MW3011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending IV doses administered per protocol
Study: NCT06772766
Drug: 9MW3011 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending IV doses administered per protocol
Study: NCT06361329
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT02465138
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketorolac
Study: NCT02465138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline
Study: NCT02201381
Drug: Metabolic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
Study: NCT06281951
Drug: Fentanyl - Inhalation by facial nebulization
Normalized name: fentanyl Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 administrations based on a weight-dependent threshold (40 µg per administration for a weight \< 70kg and 50 µg per administration for a weight ≥ 70kg).
Study: NCT06281951
Drug: Fentanyl - Nebulisation
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 administrations based on a weight-dependent threshold (20 µg/administration and for a weight \< 70kg and 30 µg/administration for a weight ≥ 70kg). The dose of each bolus will be distributed at equivalent volume in both nasal pits
Study: NCT06782594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, iv, bid, for 3 to 5 days
Study: NCT04942171
Drug: Medical therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Use of beta-blockers or calcium channel blockers for pulse rate control~2. Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~3. If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~4. To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~5. Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure
Study: NCT06295432
Drug: DZD9008+AZD4205
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
Study: NCT06787222
Drug: tretinoin 0.025% + Z. officinale patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Material used for patch formulation were 3,15 grams of polyvinyl alcohol, 4,2 grams of polyvinyl pyrrolidone, 12,6 ml distilled water, and 1,05 grams of Z. officinale extract.
Study: NCT06787222
Drug: tretinoin 0.025% cream
Normalized name: TRETINOIN 0.025% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: no Z. officinale patch applied after tretinoin 0.025% application
Study: NCT06792422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an oral placebo once daily.~1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)~2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)~3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)
Study: NCT06787339
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 650mg/m2, bid, p.o for 1 year
Study: NCT05983354
Drug: Oral metoclopramide and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.
Study: NCT05983354
Drug: Intravenous metoclopramide and ketorolac
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
Study: NCT06443775
Drug: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Drops
Study: NCT04337099
Drug: MBM-02 (Tempol)
Normalized name: SUS SCROFA TEMPORAL LOBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Study: NCT06765902
Drug: M-CENK
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.
Study: NCT06765252
Drug: Capecitabine-based chemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.
Study: NCT06795776
Drug: Eschscholzia tablets
Normalized name: Eschscholzia californica extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will be provided as swallowable Eschscholzia tablets (1.0 g) containing 0.503g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material.
Study: NCT06795776
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants.
Study: NCT06769113
Drug: HLX43 DOSE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06769113
Drug: HLX43 DOSE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06474533
Drug: Fluorethyltyrosine (18-F)
Normalized name: Fluorethyltyrosine (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously (IV)
Study: NCT06347133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile normal saline (0.9% NaCl)
Study: NCT05539963
Drug: STIMULAN VG
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive STIMULAN VG via implantation during debridement surgery on Day 1.
Study: NCT06564818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05028387
Drug: medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical abortion
Study: NCT06483789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo will be supplied as a tablet.
Study: NCT05835999
Drug: Placebo once per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapeutic effect
Study: NCT05835999
Drug: Placebo once per week
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapeutic effect
Study: NCT06555328
Drug: CSU lower dose treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSU lower dose treatment
Study: NCT04997525
Drug: Estradiol Tablets
Normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined with progesterone
Study: NCT05026125
Drug: Remifentanil Injection
Normalized name: remifentanil Injection
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Study: NCT05026125
Drug: Remifentanil Injection plus 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Study: NCT04994132
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT06746870
Drug: IMM2510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion
Study: NCT06747156
Drug: ABO2203 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Name of Active Ingredient: mRNA encoding CD19/CD3 T cell engager
Study: NCT05155306
Drug: BI 1358894, intended Commercial Formulation (iCF) (T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning
Study: NCT05006794
Drug: zamzetoclax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally
Study: NCT06019728
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet or solution; Oral
Study: NCT05477589
Drug: busulfan, cyclophosphamide and melphalan, BuCyMel
Approvals — FDA: no, EMA: no, PMDA: no
Description: a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
Study: NCT06100822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg capsules of placebo pills
Study: NCT05082974
Drug: OC-01 (varenicline 0.6mg/ml) nasal spray
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
Study: NCT05082974
Drug: Placebo (vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) nasal spray \[control\]
Study: NCT05116774
Drug: BCX9930
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally twice daily
Study: NCT06756828
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3months melatonin
Study: NCT06759948
Drug: GC012F injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows:~1. Dose group 1: 1 × 10\^5/kg;~2. Dose group 2: 2 × 10\^5/kg;~3. Dose group 3: 3 × 10\^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10\^5 × 70 kg.
Study: NCT06760039
Drug: R-CMOP Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab intravenous drip, Cyclophosphamide intravenous drip, Liposomal Mitoxantrone intravenous drip, Vincristine intravenous drip, Prednisone orally
Study: NCT06760039
Drug: R-CHOP Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab intravenous drip, Cyclophosphamide intravenous drip, Doxorubicinin intravenous drip, Vincristine intravenous drip, Prednisone orally
Study: NCT06418061
Drug: IBI3005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
Study: NCT06428825
Drug: BAY3283142
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT06428825
Drug: Placebo to BAY3283142
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05394246
Drug: FluoAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Injection: FluoAB (fluorescent-labeled IgG)
Study: NCT04880564
Drug: CN1, 0.5mg/kg and CN401, 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
Study: NCT04880564
Drug: CN1, 1mg/kg and CN401, 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
Study: NCT04880564
Drug: CN1, 1mg/kg and CN401, 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Study: NCT04880564
Drug: CN1, 3mg/kg and CN401, 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Study: NCT04880564
Drug: CN1, 10mg/kg and CN401, 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Study: NCT06603623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT05375903
Drug: UGN-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).
Study: NCT06754891
Drug: TQH3906 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH3906 is an allosteric inhibitor targeting kinase.
Study: NCT06764966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Once Daily along with previously prescribed Non Selective Beta Blocker
Study: NCT06734975
Drug: Superior laryngeal nerve block - Placebo (saline)
Normalized name: ACS22Q55 NERVE BLOCK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
Study: NCT06739473
Drug: CEUS or Contrast enhanced Ultrasound
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia
Study: NCT06736912
Drug: IN-114199 2.5mg or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN-114199 2.5mg or placebo (1 Tablet, QD)
Study: NCT05919615
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride normal saline
Study: NCT05851027
Drug: QL0911
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study: NCT06759298
Drug: matched placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gtoup will recieve matched placebo tablet
Study: NCT06751108
Drug: Corticosteroids (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of immune checkpoint inhibitors and corticosteroids
Study: NCT06791512
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control group will receive the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) alone.
Study: NCT06199349
Drug: GMDTC for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Study: NCT06570577
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Pain Management
Study: NCT06469151
Drug: AZD5148
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus
Study: NCT06469151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus
Study: NCT06783309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride for injection
Study: NCT06581380
Drug: JK-1201I
Approvals — FDA: no, EMA: no, PMDA: no
Description: JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.
Study: NCT06795165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT06740422
Drug: Xuanhuang Runtong Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.
Study: NCT05453136
Drug: TS-142 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received repeated doses of 5 mg of TS-142 (oral tablet)
Study: NCT05453136
Drug: TS-142 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received repeated doses of 10 mg of TS-142 (oral tablet)
Study: NCT05453136
Drug: Placebo to TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received repeated doses of placebo to TS-142 (oral tablet)
Study: NCT06793293
Drug: Non-steroidal anti- inflammatory drugs and antibiotics
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) only.
Study: NCT06757244
Drug: mFOLFIRINOX Treatment Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX d1, d15, d29 cycle 1 to cycle 4 is administered as follow: oxaliplatin 85 mg/m2 on day1, IV infusion over 2 h, immediately followed by folinic acid 400 mg/m2 or calcium levofolinate 200 mg/m2 given as a 2-h IV infusion, with the addition of irinotecan 180 mg/m2 as per dose-level given as a 90-min intravenous infusion through a Y-connector immediately followed by 5- fluorouracil 2400 mg/m2 over 46 h continuous infusion.